Αναστολέας του σημείου ελέγχου (checkpoint inhibitor) που χρησιμοποιείται σε καρκίνους προχωρημένου σταδίου.
Βιβλιογραφική Τεκμηρίωση:
Nivolumab for the treatment of colorectal cancer.Smith KM, Desai J.Expert Rev Anticancer Ther. 2018 Jul;18(7):611-618.
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT.J Clin Oncol. 2018 Oct 1;36(28):2836-2844.
Adjuvant Nivolumab in Esophageal Cancer - A New Standard of Care. Ilson DH.N Engl J Med. 2021 Apr 1;384(13):1269-1271.
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. Ready NE, Ott PA, Hellmann MD, Zugazagoitia J, Hann CL, de Braud F, Antonia SJ, Ascierto PA, Moreno V, Atmaca A, Salvagni S, Taylor M, Amin A, Camidge DR, Horn L, Calvo E, Li A, Lin WH, Callahan MK, Spigel DR.J Thorac Oncol. 2020 Mar;15(3):426-435
Nivolumab for the treatment of hepatocellular carcinoma.Finkelmeier F, Waidmann O, Trojan J.Expert Rev Anticancer Ther. 2018 Dec;18(12):1169-1175.
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML.Oral Oncol. 2018 Jun;81:45-51.
nivolumab
